+

WO2009141541A3 - Utilisation d' inhibiteurs de kif13a et d ' ap-1 pour inhiber la melanogenese - Google Patents

Utilisation d' inhibiteurs de kif13a et d ' ap-1 pour inhiber la melanogenese Download PDF

Info

Publication number
WO2009141541A3
WO2009141541A3 PCT/FR2009/050737 FR2009050737W WO2009141541A3 WO 2009141541 A3 WO2009141541 A3 WO 2009141541A3 FR 2009050737 W FR2009050737 W FR 2009050737W WO 2009141541 A3 WO2009141541 A3 WO 2009141541A3
Authority
WO
WIPO (PCT)
Prior art keywords
kif13a
inhibitors
inhibiting melanogenesis
kinesin
subunit
Prior art date
Application number
PCT/FR2009/050737
Other languages
English (en)
Other versions
WO2009141541A2 (fr
Inventor
Graça RAPOSO
Cédric DELEVOYE
Danièle TENZA
Ilse Hurbain
Original Assignee
Centre National De La Recherche Scientifique
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0852696A external-priority patent/FR2930152A1/fr
Priority claimed from FR0852692A external-priority patent/FR2930151A1/fr
Application filed by Centre National De La Recherche Scientifique, Institut Curie filed Critical Centre National De La Recherche Scientifique
Priority to EP09750022A priority Critical patent/EP2276455A2/fr
Priority to CN200980114392.1A priority patent/CN102014859B/zh
Priority to US12/988,570 priority patent/US20110038853A1/en
Priority to CA2720664A priority patent/CA2720664A1/fr
Priority to JP2011505573A priority patent/JP5462862B2/ja
Publication of WO2009141541A2 publication Critical patent/WO2009141541A2/fr
Publication of WO2009141541A3 publication Critical patent/WO2009141541A3/fr
Priority to US13/569,576 priority patent/US8669238B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Birds (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne de nouvelles compositions pharmaceutiques ou cosmétiques comprenant au moins un inhibiteur d'une sous-unité du complexe adaptateur AP-1, d'une kinésine interagissant avec AP-1, en particulier Kif13A, ou de l'interaction entre une sous- unité du complexe adaptateur AP-1 et ladite kinésine, ainsi que leur utilisation pour la fabrication d'un médicament destiné au traitement de troubles pigmentaire et comme agent dépigmentant.
PCT/FR2009/050737 2008-04-22 2009-04-21 Nouvelles compositions inhibant la melanogenese et leurs utilisations WO2009141541A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP09750022A EP2276455A2 (fr) 2008-04-22 2009-04-21 Utilisation d'inhibiteurs de kif13a et d'ap-1 pour inhiber la mélanogénèse
CN200980114392.1A CN102014859B (zh) 2008-04-22 2009-04-21 抑制黑素生成的新组合物及其应用
US12/988,570 US20110038853A1 (en) 2008-04-22 2009-04-21 Use of Kif13A and AP-1 Inhibitors for Inhibiting Melanogenesis
CA2720664A CA2720664A1 (fr) 2008-04-22 2009-04-21 Nouvelles compositions inhibant la melanogenese et leurs utilisations
JP2011505573A JP5462862B2 (ja) 2008-04-22 2009-04-21 メラニン形成を阻害するためのＫｉｆ１３Ａ阻害剤およびＡＰ−１阻害剤の使用
US13/569,576 US8669238B2 (en) 2008-04-22 2012-08-08 Use of Kif13A and AP-1 inhibitors for inhibiting melanogenesis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0852696 2008-04-22
FR0852696A FR2930152A1 (fr) 2008-04-22 2008-04-22 Nouvelles compositions inhibant la melanogenese et leurs utilisations
FR0852692 2008-04-22
FR0852692A FR2930151A1 (fr) 2008-04-22 2008-04-22 Nouvelles compositions inhibant la melanogenese et leurs utilisations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/988,570 A-371-Of-International US20110038853A1 (en) 2008-04-22 2009-04-21 Use of Kif13A and AP-1 Inhibitors for Inhibiting Melanogenesis
US13/569,576 Division US8669238B2 (en) 2008-04-22 2012-08-08 Use of Kif13A and AP-1 inhibitors for inhibiting melanogenesis

Publications (2)

Publication Number Publication Date
WO2009141541A2 WO2009141541A2 (fr) 2009-11-26
WO2009141541A3 true WO2009141541A3 (fr) 2010-04-29

Family

ID=41340615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/050737 WO2009141541A2 (fr) 2008-04-22 2009-04-21 Nouvelles compositions inhibant la melanogenese et leurs utilisations

Country Status (6)

Country Link
US (2) US20110038853A1 (fr)
EP (1) EP2276455A2 (fr)
JP (1) JP5462862B2 (fr)
CN (1) CN102014859B (fr)
CA (1) CA2720664A1 (fr)
WO (1) WO2009141541A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2958845B1 (fr) * 2010-04-16 2012-06-01 Clc Technologie Nouvelles compositions depigmentantes
JP6132456B2 (ja) * 2011-04-14 2017-05-24 一丸ファルコス株式会社 キネシン抑制剤
JP6130989B2 (ja) * 2011-04-14 2017-05-17 一丸ファルコス株式会社 キネシン抑制剤
JP5756326B2 (ja) * 2011-04-14 2015-07-29 一丸ファルコス株式会社 キネシン抑制剤
EA201400911A1 (ru) 2012-02-13 2014-11-28 Юнилевер Н.В. Осветляющая кожу композиция
JP2013166712A (ja) * 2012-02-14 2013-08-29 Ichimaru Pharcos Co Ltd キネシン抑制剤
JP6029284B2 (ja) * 2012-02-14 2016-11-24 一丸ファルコス株式会社 キネシン抑制剤
JP2014141475A (ja) * 2012-12-27 2014-08-07 Daiichi Sankyo Co Ltd 新規美白剤
WO2016006744A1 (fr) * 2014-07-11 2016-01-14 주식회사 프로셀테라퓨틱스 Complexe peptide-petit arni pour administration transdermale au moyen de peptides de transport moléculaire intracellulaire et utilisation associée
EP2990027A1 (fr) 2014-09-01 2016-03-02 Institut Curie Agents peptidiques blanchissants pour la peau
CN106070537A (zh) * 2016-07-08 2016-11-09 广东海洋大学 一种抑制虾黑变的抗氧化剂及其制备方法与应用
JP6324458B2 (ja) * 2016-09-21 2018-05-16 一丸ファルコス株式会社 キネシン抑制剤
CN108969465B (zh) * 2018-08-15 2021-11-23 吉安智企企业服务有限公司 清爽舒缓隔离防晒乳及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058918A2 (fr) * 2000-02-11 2001-08-16 Lvmh Recherche Oligonucleotides modulant l'expression d'enzymes intervenant dansla synthese de pigments melaniques
WO2001089502A2 (fr) * 2000-05-22 2001-11-29 The Regents Of The University Of Michigan Compositions et procedes a utiliser contre l'inflammation induite par l'acne et les enzymes degradant la matrice dermique
US20020128291A1 (en) * 1995-02-01 2002-09-12 Allergan, California Corporation Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
WO2007148697A1 (fr) * 2006-06-22 2007-12-27 Arkray, Inc. Inhibiteur de l'expression du facteur de transcription nucléaire ap-1, et produits pharmaceutiques ou autres utilisant cet inhibiteur

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2002089743A2 (fr) * 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Compositions pour le traitement de l'acne rosacee
US7700076B2 (en) * 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
PT2284266E (pt) * 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
WO2008043561A2 (fr) * 2006-10-11 2008-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cibles de la grippe

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128291A1 (en) * 1995-02-01 2002-09-12 Allergan, California Corporation Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
WO2001058918A2 (fr) * 2000-02-11 2001-08-16 Lvmh Recherche Oligonucleotides modulant l'expression d'enzymes intervenant dansla synthese de pigments melaniques
WO2001089502A2 (fr) * 2000-05-22 2001-11-29 The Regents Of The University Of Michigan Compositions et procedes a utiliser contre l'inflammation induite par l'acne et les enzymes degradant la matrice dermique
WO2007148697A1 (fr) * 2006-06-22 2007-12-27 Arkray, Inc. Inhibiteur de l'expression du facteur de transcription nucléaire ap-1, et produits pharmaceutiques ou autres utilisant cet inhibiteur

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRAUN V ET AL: "AP-1 and ARF-1 control endosomal dynamics at sites of FcR-mediated phagocytosis", MOLECULAR BIOLOGY OF THE CELL, BETHESDA, MD, US, vol. 18, 1 December 2007 (2007-12-01), pages 4921 - 4931, XP002509594, ISSN: 1059-1524, [retrieved on 20071003] *
DATABASE WPI Week 200850, Derwent World Patents Index; AN 2008-H91922 *
HIRST J ET AL: "EpsinR : an ENTH domain-containing protein that interacts with AP-1", MOLECULAR BIOLOGY OF THE CELL, BETHESDA, MD, US, vol. 14, 1 February 2003 (2003-02-01), pages 625 - 641, XP002509595, ISSN: 1059-1524 *
NAKAGAWA T. ET AL.: "A novel motor, KIF13A, transports mannose-6-phosphate receptor to plasma membrane thriugh direct interaction with AP-1 complex.", CELL, vol. 103, 2000, pages 569 - 581, XP002509746 *
VALENCIA J C ET AL: "Sorting of Pmel17to melanosomes through the plasma membrane by AP1 and Ap2 : evidence of the polarized nature of melanocytes", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 119, 1 January 2006 (2006-01-01), pages 1080 - 1091, XP002509596, ISSN: 0021-9533 *
WONDERLICH E.R. ET AL.: "The tyrosine binding pocket in the adaptor protein 1 (AP-1) mu1 subunit is necessary for Nef to recruit AP-1 to the major histocompatibility complex class I cytoplasmic tail.", J. BIOL. CHEM., vol. 283, 8 February 2008 (2008-02-08), pages 3011 - 3022, XP002571580 *

Also Published As

Publication number Publication date
US20120321575A1 (en) 2012-12-20
JP5462862B2 (ja) 2014-04-02
US20110038853A1 (en) 2011-02-17
CN102014859B (zh) 2015-05-20
US8669238B2 (en) 2014-03-11
CA2720664A1 (fr) 2009-11-26
CN102014859A (zh) 2011-04-13
EP2276455A2 (fr) 2011-01-26
WO2009141541A2 (fr) 2009-11-26
JP2011518214A (ja) 2011-06-23

Similar Documents

Publication Publication Date Title
WO2009141541A3 (fr) Utilisation d' inhibiteurs de kif13a et d ' ap-1 pour inhiber la melanogenese
WO2010132882A3 (fr) Compositions sublinguales de dexmédétomidine et leurs procédés d'utilisation
WO2012046030A3 (fr) Inhibiteurs de phosphodiestérase
WO2009074735A8 (fr) Utilisation d'un nouvel agent naturel dans des compositions cosmetiques
WO2010127099A3 (fr) Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
IN2012DN01233A (fr)
WO2011044506A3 (fr) Composés sulfonés et leurs procédés de fabrication et d'utilisation
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
WO2010009127A3 (fr) Compositions de blanchiment des dents et procédés
WO2010033977A3 (fr) Composes multiheteroaryles servant d'inhibiteurs de la h-pgds, ainsi que leur utilisation dans le traitement des maladies induites par la prostaglandine d2
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
WO2010135530A3 (fr) Composés, compositions et procédés pour moduler des taux d'acide urique
WO2009012871A3 (fr) Capsule filtrant les uv
WO2006116221A3 (fr) Nouvelles combinaisons therapeutiques pour le traitement ou la prevention de troubles psychotiques
WO2010121164A3 (fr) Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
WO2009035634A3 (fr) Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu'inhibiteurs de gsk-3
WO2008107092A3 (fr) Utilisation de dérivés d'acide 4-hydroxyphénoxy acétique
WO2009099553A3 (fr) Utilisation d’inhibiteur de kinase pour le traitement de l’athérosclérose
WO2008031940A3 (fr) Composition a base de xanthoxyline et son utilisation en cosmetique.
IL215840A (en) Arylsulfonamide compounds are converted into two positions 2 and 5, their pharmaceutical composition containing them and their use in the treatment of ccr3-related diseases
WO2010062506A3 (fr) Inhibiteurs de cyp17 décahydro-1h-indénoquinolinone et décahydro-3h-cyclopentaphénanthridinone
WO2011088160A3 (fr) Nouveaux inhibiteurs de cyp17
MX2009012712A (es) Nuevas 4-fenil-imidazol-2-tionas como inhibidores de la tirosinasa, su procedimiento de preparacion y su uso en medicina humana asi como en cosmetica.
WO2008094054A3 (fr) Composés

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980114392.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09750022

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2720664

Country of ref document: CA

Ref document number: 2009750022

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12988570

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011505573

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载